Eslicarbazepine acetate in partial onset seizures – data from EAN 2015

Three abstracts presented at the 1st Annual EAN Congress 2015 (20–23 June 2015, Berlin, Germany) discussed the latest data on the use of eslicarbazepine acetate as add-on treatment to antieplileptic monotherapy in adults with partial-onset seizures (POS). These abstracts were discussed by Martin Holtkamp, Medical Director at the Epilepsy Center, Berlin-Brandenburg (Germany) at the ‘Advances in Epilepsy Management Press Conference’, sponsored by Eisai. Eslicarbazepine acetate was originally granted EU marketing authorization in 2009 for use as adjunctive therapy in adults with POS or without second generalization. The drug was subsequently approved by the FDA as an adjunctive treatment of POS...